Proteome Integral Solubility Alteration (PISA) assay is normally used for characterization of the interactions between a small molecule and the cellular proteome. Here we modified PISA uniquely to identify the antigen (tumor necrosis factor alpha) in activated monocytes using the monoclonal antibody Infliximab.